Trastuzumab with Low-Dose Chemotherapy for Metastatic Breast Cancer
Author Information
Author(s): Orlando Laura, Cardillo Anna, Ghisini Raffaella, Rocca Andrea, Balduzzi Alessandra, Torrisi Rosalba, Peruzzotti Giulia, Goldhirsch Aron, Pietri Elisabetta, Colleoni Marco
Primary Institution: European Institute of Oncology
Hypothesis
The combination of Trastuzumab with metronomic chemotherapy will be effective in patients with HER-2 positive metastatic breast cancer.
Conclusion
The combination of trastuzumab and metronomic chemotherapy is effective and minimally toxic in advanced breast cancer patients.
Supporting Evidence
- The study included 22 patients with HER2-positive metastatic breast cancer.
- Patients had previously received trastuzumab and other treatments.
- The treatment resulted in 4 partial remissions and 10 stable disease cases.
Takeaway
This study tested a new treatment for breast cancer that combines a drug called trastuzumab with low doses of chemotherapy, and it worked well for many patients.
Methodology
Patients were treated with trastuzumab, cyclophosphamide, and methotrexate, and their responses were evaluated over time.
Potential Biases
Potential bias due to the non-randomized design and small sample size.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Patients were mostly women with HER2-positive metastatic breast cancer, median age 48.9 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI 5–40%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website